SCHEMBL3836458

SCHEMBL3836458

CC(C)(C)OC(=O)N[C@H]1CC[C@@](O)(C#Cc2cccc(Cl)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 10/20 0.52
DRD2 P14416 3/20 0.41
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40
MAPK8 P45983 1/20 0.40
DRD3 P35462 1/20 0.40
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CACNB4 O00305 1/20 0.39
CACNA1A O00555 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNG3 O60359 1/20 0.39
CACNA1F O60840 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNB3 P54284 1/20 0.39
CACNA2D1 P54289 1/20 0.39
CACNG7 P62955 1/20 0.39
CACNA1B Q00975 1/20 0.39
CACNA1D Q01668 1/20 0.39
CACNB1 Q02641 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3836455 1.00 GRM5 (0.52) GRM5DRD2KDM1AMAOBMAPK8
SCHEMBL3860245 1.00 GRM5 (0.52) GRM5DRD2KDM1AMAOBMAPK8
SCHEMBL3836423 0.89 GRM5 (0.58) GRM5L3MBTL1
SCHEMBL3837282 0.89 GRM5 (0.58) GRM5L3MBTL1
SCHEMBL3836422 0.89 GRM5 (0.58) GRM5L3MBTL1
SCHEMBL4656464 0.88 GRM5 (0.51) GRM5MAPK8KMT2AL3MBTL1
SCHEMBL3276845 0.88 GRM5 (0.51) GRM5MAPK8KMT2AL3MBTL1
SCHEMBL3276840 0.88 GRM5 (0.51) GRM5MAPK8KMT2AL3MBTL1
SCHEMBL3276839 0.88 GRM5 (0.51) GRM5MAPK8KMT2AL3MBTL1
SCHEMBL3276822 0.88 GRM5 (0.51) GRM5MAPK8KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877367-B1 ACETYLENE DERIVATIVES NOVARTIS AG (CH) 2009-10-14 EP disclosed
US-20080194551-A1 Acetylene Derivatives NOVARTIS PHARMA GMBH (AT) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194551-A1 Acetylene Derivatives NAT1, B3GNT2, NAT10 GRM5 3731/4885DRD2 1243/4885KDM1A 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.